Yasser Abdel Azim
About Yasser Abdel Azim
Yasser Abdel Azim is the Country Manager at Bristol-Myers Squibb, with over 30 years of experience in the pharmaceutical industry.
Country Manager at Bristol-Myers Squibb
Yasser Abdel Azim holds the position of Country Manager at Bristol-Myers Squibb. In this role, he oversees operations within Egypt, ensuring that the company’s strategic goals are met within the region. His responsibilities include managing day-to-day operations, leading team projects, and ensuring compliance with industry regulations. This role leverages his extensive experience in the pharmaceutical industry to drive growth and efficiency in the market.
Career at Bristol-Myers Squibb
Yasser Abdel Azim has dedicated over three decades to working at Bristol-Myers Squibb, beginning his career with the company in 1990. He initially served as a Sales Manager in New York, New York, before transitioning to his current role as Country Manager in Egypt. His long tenure at the company highlights his deep commitment and substantial contributions to its success. Throughout his career, he has gained extensive expertise and built a robust understanding of the pharmaceutical landscape.
Education in Pharmacy
Yasser Abdel Azim pursued his higher education at Pharmacy College, where he achieved a bachelor's degree. He studied from 1979 to 1984, completing a rigorous five-year program. This academic background laid the foundational knowledge for his long and successful career in the pharmaceutical industry. His studies have equipped him with the technical and scientific understanding necessary to excel in his professional roles.
Pharmaceutical Industry Experience
With over 30 years in the pharmaceutical industry, Yasser Abdel Azim brings a wealth of experience to his position. His career has spanned various roles and responsibilities, allowing him to build a comprehensive understanding of the industry. His experience includes strategic planning, sales management, and country oversight, enabling him to contribute significantly to Bristol-Myers Squibb's operations and growth.